Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa and Xeloda in Advanced Colorectal Carcinoma
NCT00242788Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in colorectal carcinoma (CRC), sponsored by AstraZeneca. Primary endpoints: Recommended dose of capecitabine in combination with ZD1839 and Objective Tumour Response. Started Feb 2004; status: completed.
02
Drugs
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00242788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242788.